Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532247 | 0.84 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL366727 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL3168607 | 0.82 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1504021 | 0.82 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1012343 | 0.82 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL31265664 | 0.81 | NPC1 (0.45) | PTGS2NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1283896 | 0.81 | CDK8 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL274692 | 0.81 | NPC1 (0.57) | PTGS2PTGS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4056715 | 0.81 | NPC1 (0.45) | PTGS2PTGS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1013888 | 0.81 | PRKCZ (0.53) | PTGS2PTGS1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | PTGS2 302/4885PTGS1 109/4885NPC1 1088/4885 |
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | PTGS2 493/4885PTGS1 189/4885NPC1 1221/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | PTGS2 354/4885PTGS1 84/4885NPC1 547/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | PTGS2 720/4885PTGS1 315/4885NPC1 3313/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | PTGS2 636/4885PTGS1 299/4885NPC1 3390/4885 |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | PTGS2 151/4885PTGS1 69/4885NPC1 3262/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | PTGS2 354/4885PTGS1 84/4885NPC1 547/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | PTGS2 314/4885PTGS1 113/4885NPC1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.